Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial

Bi-weekly cofrogliptin treatment, instead of daily DPP-4i, could effectively control blood glucose levels in a 24-week treatment period and their fluctuations and was well tolerated in Chinese patients with T2DM.